AXSM
$161.17
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Recent News
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference
Axsome Therapeutics (NASDAQ:AXSM) executives highlighted accelerating commercial momentum, a near-term regulatory catalyst, and a broad late-stage pipeline during a presentation at the Citizens JMP Life Sciences Conference. 2025 performance and near-term focus Chief Operating Officer Mark Jacobson
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth
Axsome Therapeutics (AXSM) is back in focus after the FDA granted Priority Review to its AXS-05 program for Alzheimer's disease agitation, alongside reported 66% full-year 2025 net product revenue growth that is drawing fresh investor attention. See our latest analysis for Axsome Therapeutics. At a share price of $164.49, Axsome’s recent 13.27% 90 day share price return and 38.48% 1 year total shareholder return suggest momentum has picked up again after a softer year to date performance,...
2 Under-the-Radar Stocks to Buy and Hold
These biotechs are slowly making a name for themselves.
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates
Axsome Therapeutics (NASDAQ:AXSM) executives provided updates on the company’s commercial portfolio and pipeline during a discussion hosted by Leerink Partners biopharma analyst Marc Goodman. Mark Jacobson, the company’s COO, and Nick Pizzie, CFO, outlined plans for the antidepressant Auvelity, the